Company intelligence / Profile preview
Shandong Qilu Stem Cell Engineering
Jinan (presumed HQ), Shandong, Chinaql-cellbank.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company conducts clinical-stage research primarily in stem cell therapies and CAR-T, with clinical programs in decompensated liver cirrhosis (Phase 1/2), allergic rhinitis (clinical), and preclinical CAR-T targeting CD19 for leukemia; early-stage for other indications; it is regarded as one of China's leading full-chain cell therapy groups
- Therapeutic areas
- ImmunologyNephrologyRheumatologyGastroenterologyOncology
- Modalities
- Stem cell therapyCAR-T cell therapyMesenchymal stem cell therapyAdipose-derived stem cell therapy
- Industry
- Biotech
02
Drug pipeline
13 assets12 more assets in the full pipeline.
03
Partnerships
Qilu Hospital (joint venture in Shandong Cord Blood Bank)Sanpower Group (ownership/strategic support)
Beyond the preview
Go deeper on Shandong Qilu Stem Cell Engineering.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shandong Qilu Stem Cell Engineering.